Company:pSivida
From HandWiki
Revision as of 20:43, 18 September 2021 by imported>JOpenQuest (linkage)
| Type | Public company |
|---|---|
| NASDAQ: PSDV ASX: PVA FWB: PV3 | |
| Industry | Pharmaceuticals |
| Headquarters | Watertown, Massachusetts , |
Number of locations | 2 |
| Products | Iluvien |
| Website | www |
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).[citation needed] QinetiQ continues to be a strategic partner.[1][2]
In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4]
See also
- Alimera Sciences, pSvida's partner on Iluvien
References
- ↑ 1.0 1.1 "PSivida lifts pSiMedica stake to 100%" (in en). 2004-06-02. https://www.smh.com.au/business/psivida-lifts-psimedica-stake-to-100-percent-20040602-gdj1pl.html.
- ↑ "Nano silicon boosts tumour fight" (in en-GB). 2004-06-18. http://news.bbc.co.uk/2/hi/science/nature/3812987.stm.
- ↑ "BRIEF—pSivida to buy eye products firm Icon Bioscience" (in en). https://www.thepharmaletter.com/in-brief/brief-psivida-to-buy-eye-products-firm-icon-bioscience.
- ↑ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience" (in en). Reuters. 2018-03-28. https://www.reuters.com/article/brief-psivida-corp-announces-transformat-idUSASC09U27.
External links
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. http://www.streetinsider.com/Corporate+News/pSivida+%28PSDV%29+Enters+Two+Funded+Evaluation+Agreements+with+Leading+Pharma/10549297.html. Retrieved May 15, 2015.
- Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. http://www.benzinga.com/news/14/05/4526694/update-psivida-issues-presentation-of-preclinical-data-showing-sustained-release-#ixzz3aCmpcXjP. Retrieved May 15, 2015. "pSivida's Dinesh K. Nadarassan presented a poster entitled “Sustained Release of Bevacizumab (Avastin) from BioSilicon”"
- pSivida Mesoporous silicon patent
 |  |
